VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Up 470.4% in June

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 113,911 shares, a growth of 470.4% from the June 15th total of 19,972 shares. Approximately 4.5% of the company’s shares are short sold. Based on an average trading volume of 157,314 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

VivoSim Labs Stock Performance

Shares of VIVS stock traded up $0.08 during trading hours on Friday, hitting $0.88. 937,322 shares of the company were exchanged, compared to its average volume of 121,012. The company has a 50 day simple moving average of $1.19 and a two-hundred day simple moving average of $1.63. The firm has a market cap of $2.29 million, a P/E ratio of -0.28 and a beta of 1.40. VivoSim Labs has a fifty-two week low of $0.78 and a fifty-two week high of $5.30.

Institutional Investors Weigh In On VivoSim Labs

A hedge fund recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP purchased a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is owned by institutional investors and hedge funds.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.